ClinicalTrials.gov

History of Changes for Study: NCT02472964
Study of Efficacy and Safety of Hercules(Myl1401O Mylan Trastuzumab) + Taxane vs Herceptin©+ Taxane for 1st Line, Met. Br. Ca. (HERiTAge)
Latest version (submitted February 10, 2022) on ClinicalTrials.gov
  • A study version is represented by a row in the table.
  • Select two study versions to compare. One each from columns A and B.
  • Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side format only applies to the Protocol section of the study.
  • Click "Compare" to do the comparison and show the differences.
  • Select a version's Submitted Date link to see a rendering of the study for that version.
  • The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently being viewed.
  • Hover over the "Recruitment Status" to see how the study's recruitment status changed.
  • Study edits or deletions are displayed in red.
  • Study additions are displayed in green.
Study Record Versions
Version A B Submitted Date Changes
1 June 11, 2015 None (earliest Version on record)
2 July 7, 2015 Recruitment Status, Study Status and Contacts/Locations
3 March 15, 2016 Study Status
4 May 12, 2016 Study Status and Study Identification
Show
Results Submission Events
5 October 29, 2018 Recruitment Status, Study Status, Arms and Interventions, Outcome Measures, Study Design, Study Identification, Results and Study Description
6 February 10, 2022 Study Status and Study Identification
Comparison Format:

Scroll up to access the controls

Study NCT02472964
Submitted Date:  June 11, 2015 (v1)

Open or close this module Study Identification
Unique Protocol ID: MYL-Her3001
Brief Title: Study of Efficacy and Safety of Hercules(Myl1401O Mylan Trastuzumab) + Taxane vs Herceptin©+ Taxane for 1st Line, Met. Br. Ca. (HERiTAge)
Official Title: A Multicenter, Double-Blind, Randomized, Parallel-Group, Phase III Study To Compare The Efficacy And Safety Of Hercules Versus Herceptin® In Patients With HER2+ Metastatic Breast Cancer
Secondary IDs: 2011-001965-42 [EudraCT Number]
Open or close this module Study Status
Record Verification: June 2015
Overall Status: Recruiting
Study Start: July 2012
Primary Completion: January 2016 [Anticipated]
Study Completion: December 2018 [Anticipated]
First Submitted: June 3, 2015
First Submitted that
Met QC Criteria:
June 11, 2015
First Posted: June 16, 2015 [Estimate]
Last Update Submitted that
Met QC Criteria:
June 11, 2015
Last Update Posted: June 16, 2015 [Estimate]
Open or close this module Sponsor/Collaborators
Sponsor: Mylan Inc.
Responsible Party: Sponsor
Collaborators: Mylan GmbH
Open or close this module Oversight
U.S. FDA-regulated Drug:
U.S. FDA-regulated Device:
Data Monitoring: Yes
Open or close this module Study Description
Brief Summary: A multicenter, double-blind, randomized, parallel-group, Phase III study of the efficacy and safety of Hercules( Myl 1401O, Mylan Trastuzumab) plus taxane versus Herceptin® plus taxane as first line therapy in patients with HER2-positive metastatic breast cancer.
Detailed Description:

Part 1: A multicenter, double-blind, randomized, parallel-group, Phase III study to compare the efficacy and safety of Hercules( Myl 1401O, Mylan Trastuzumab) plus taxane versus Herceptin® plus taxane in patients with HER2+ MBC. Either docetaxel or paclitaxel (Investigator site level choice) is planned for at least 24 weeks until documented response to therapy, disease progression, or discontinuation. Disease response and progression will be assessed locally by the Investigator on the basis of clinical and radiographic evidence using RECIST 1.1 criteria. The primary and secondary efficacy analyses will be performed using independently assessed radiographic evidence for the Intent-to-Treat (ITT) population. The primary analysis population for best ORR will be those patients who had measureable disease at baseline and for the secondary endpoint, DR, only those who are responders will be included in the analysis.

Part 2: A multicenter, double-blind, parallel-group study to continue to compare the safety and immunogenicity and efficacy of Hercules( Myl 1401O, Mylan Trastuzumab) versus Herceptin® in patients with HER2+ MBC who have clinical benefit to first-line combination therapy with a taxane. All patients who have at least stable disease (SD), will continue with either single agent Hercules( Myl 1401O, Mylan Trastuzumab) or Herceptin® alone until death, unacceptable toxicity or disease progression.

Population pharmacokinetics: During Part 1 of the study, for both the Hercules ( Myl 1401O, Mylan Trastuzumab)and Herceptin® treatment arms, PK sampling for Cmin and Cmax (end of infusion) will be collected for all patients. A PopPK subset, with sufficient samples available to perform the necessary analysis of PopPK modeling will be used to assess AUC, Cmax, Cmin, clearance, Vd, and T1/2 at various time points in the PopPK. Patients randomized into the main study will sign an additional consent form for the PopPK subset. We anticipate that approximately 80 patients will need to be enrolled in this subset collection in order to obtain sufficient samples for analysis.

Long term survival follow-up: OS for this treated population will be determined with every 3 month follow-up until either 240 deaths or 36 months, whichever occurs first, as observed from the time of randomization.

Exploratory evaluations: In addition, during Part 1 of the study, blood samples will be collected in all patients to assess the impact of soluble shed HER2/ECD on PK and efficacy at pre-dose on Cycles 1, 3, 5, 7, and end of treatment (EOT). Additional samples (ECD) will be obtained on Cycles 9, 13 and every 4 cycles thereafter, EOT and end of study (EOS) for continued evaluation of immunogenicity in patients continuing to receive therapy. A blood sample will be obtained on Cycle 1, Day 1, to be used for assay development and validation

Open or close this module Conditions
Conditions: Breast Cancer
Keywords:
Open or close this module Study Design
Study Type: Interventional
Primary Purpose: Treatment
Study Phase: Phase 3
Interventional Study Model: Parallel Assignment
Number of Arms: 2
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Allocation: Randomized
Enrollment: 600 [Anticipated]
Open or close this module Arms and Interventions
Arms Assigned Interventions
Active Comparator: Herceptin© + Taxane

Part 1: Herceptin© (trastuzumab) intravenously+ paclitaxel 80 mg/m2 weekly intravenously or docetaxel 75 mg/m2 intravenously once every three weeks (investigators choice) for 8 cycles then evaluate for primary endpoint.

Part 2: If SD or PR, CR at cycle 9 (week 24) proceed to Herceptin© (trastuzumab) alone once every 3 weeks until DP or subject withdrawal .

Biological: Trastuzumab
Trastuzumab 8mg/kg Iv over 90 minutes x 1 then Trastuzumab 6 mg/kg IV over 30 minutes every 3 weeks
Other Names:
  • Herceptin©;
Drug: Paclitaxel
Paclitaxel 80mg/m2 IV over 60 minutes weekly.
Drug: Docetaxel
Docetaxel 75mg/m2 IV over 60 minutes on day 1 of a 3 week cycle
Experimental: HerMyl 1401O Trastuzumab + Taxane

Part 1:Myl 1401OTrastuzumab Intravenously + paclitaxel 80 mg/m2 weekly intravenously or docetaxel 75 mg/m2 intravenously once every three weeks (investigators choice) for 8 cycles then evaluate for primary endpoint.

Part 2: If SD or PR, CR at cycle 9 (week 24) proceed to Myl 1401O( Mylan Trastuzumab) alone once every 3 weeks until DP or subject withdrawal.

Biological: HERMyl 1401O Trastuzumab
HERMyl 1401O Trastuzumab 8mg/kg Iv over 90 minutes x 1 then HERMyl 1401O Trastuzumab 6 mg/kg IV over 30 minutes every 3 weeks
Other Names:
  • Hercules
Drug: Paclitaxel
Paclitaxel 80mg/m2 IV over 60 minutes weekly.
Drug: Docetaxel
Docetaxel 75mg/m2 IV over 60 minutes on day 1 of a 3 week cycle
Open or close this module Outcome Measures
Primary Outcome Measures:
1. compare best overall response rate (ORR) (according to Response Evaluation Criteria in Solid Tumor [RECIST] 1.1 criteria) at Week 24 with Hercules( Myl 1401O, Mylan Trastuzumab) in combination with taxane versus Herceptin® plus taxane
[ Time Frame: from time of First treatment to week 24 ]

RECIST 1.1 evaluation for overall response rate at 6 week intervals
Secondary Outcome Measures:
1. time to tumor progression (TTP);
[ Time Frame: from time of first treatment to week 24 at every 6 week intervals ]

2. •overall survival (OS)
[ Time Frame: from time of first treatment to week 24 at every 6 week intervals ]

3. duration of response (DR).
[ Time Frame: from time of first treatment to week 24 at every 6 week intervals ]

Open or close this module Eligibility
Minimum Age: 18 Years
Maximum Age:
Sex: All
Gender Based:
Accepts Healthy Volunteers: No
Criteria:

Inclusion Criteria:

Locally recurrent or MBC that is not amenable to curative surgery and/or radiation.

Documentation of HER2 gene amplification by fluorescent in situ hybridization (FISH) (as defined by a ratio >2.0) or documentation of HER2-overexpression by immunohistochemistry (IHC) (defined as IHC3+, or IHC2+ with FISH confirmation) based on the sponsor-identified central laboratory prior to randomization. Archival tumor tissue samples can be used.

Pathologically confirmed breast cancer with at least one measurable metastatic target lesion (based on RECIST criteria, version 1.1). Bone, central nervous system (CNS), and skin lesions, as well as lesions that were irradiated, biopsied or had any form of local intervention or surgical manipulation are only to be assessed as non-target lesions.

Patients previously treated with trastuzumab or lapatinib in the adjuvant setting are allowed if metastatic disease was diagnosed at least one year after the last dose of treatment.

Prior treatment with hormonal agents or bisphosphonates/denosumab is allowed. Bisphosphonates/denosumab can be given simultaneously with study treatment but cannot start after randomization and is considered an indication of progressive disease (PD). Hormonal agents must be discontinued prior to beginning study therapy.

Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 - 2

  • Serum creatinine ≤1.5 x ULN (upper limit of normal),
  • Total bilirubin ≤1.0 x ULN (>1.0 x ULN if documented Gilbert's disease),
  • Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) ≤2.5 x ULN,
  • AST and/or ALT <1.5 x ULN if alkaline phosphatase >2.5 x ULN,
  • Alkaline phosphatase >2.5 x ULN;if bone metastases present and no liver dysfunction present.

Left ventricular ejection fraction (LVEF) within institutional range of normal as measured by multiple gated acquisition scan or echocardiogram.

Exclusion Criteria:

Prior systemic therapy in the metastatic disease setting. This includes: chemotherapy, signal transduction inhibitors (e.g., lapatinib), HER2 targeted therapy (e.g., trastuzumab), or other investigational anticancer therapy.

Prior treatment with neoadjuvant or adjuvant anthracyclines with a cumulative dose of doxorubicin of >400 mg/m2, epirubicin dose >800 mg/m2.

Patients with bone or skin as the only site of disease. Patients with skin lesions measurable by CT scans or MRI as only site of measurable disease are allowed.

Surgery or radiotherapy ≤2 weeks preceding Day 1. Target lesions have to be outside the irradiated fields and the patient has fully recovered from surgery or radiotherapy.

Presence of unstable angina or a history of congestive heart failure according to the New York Heart Association criteria, history of myocardial infarction <1 year from randomization, clinically significant valvular disease, serious cardiac arrhythmia requiring treatment, uncontrolled hypertension or known pulmonary hypertension.

Peripheral sensory or motor neuropathy Grade 2 or higher according to the National Cancer Institute-Common Terminology Criteria (NCI-CTC) Version 4.03 [19].

Any other cancer, including contralateral breast cancer, within 5 years prior to screening with the exception of adequately treated ductal carcinoma in situ, adequately treated cervical carcinoma in situ, or adequately treated basal or squamous cell carcinoma of the skin.

Immunocompromized patients, including known seropositivity for human immunodeficiency virus, or current or chronic hepatitis B and/or hepatitis C infection (as detected by positive testing for hepatitis B surface antigen or antibody to hepatitis C virus with confirmatory testing).

Complete listing of Inc/Excl. within protocol

Open or close this module Contacts/Locations
Central Contact Person: Gail L Tribble, BSN
Telephone: 724-485-6124
Email: gail.tribble@mylan.com
Central Contact Backup: Eduardo Pennella, MD
Telephone: 724-514-2369
Email: eduardo.pennella@mylan.com
Study Officials: Eduardo Pennella, MD
Study Director
Mylan Inc.
Locations: Brazil
Mylan Investigational Site
[Not yet recruiting]
Barretos, Brazil
Mylan Investigational Site
[Not yet recruiting]
Brasilia, Brazil
Mylan Investigational Site
[Not yet recruiting]
Goiania, Brazil
Mylan Investigational Site
[Not yet recruiting]
Ijui, Brazil
Mylan Investigational Site
[Not yet recruiting]
Jau, Brazil
Mylan Investigational Site
[Not yet recruiting]
Joinville, Brazil
Mylan Investigational Site
[Not yet recruiting]
Morumbi, Brazil
Mylan Investigational Site
[Not yet recruiting]
Porto Alegre, Brazil
Mylan Investigational Site
[Not yet recruiting]
Salvador,, Brazil
Mylan Investigational Site
[Not yet recruiting]
Santo Andre, Brazil
Mylan Investigational Site
[Not yet recruiting]
Sao Paulo, Brazil
Mylan Investigational Site
[Not yet recruiting]
Sorocaba, Brazil
Chile
Mylan Investigational Site
[Recruiting]
Santiago, Chile
Mylan Investigational Site
[Recruiting]
Temuco, Chile
Georgia
Mylan Investigational Site
[Recruiting]
Batumi, Georgia
Mylan Investigational Site
[Recruiting]
Tblisi, Georgia
Hungary
Mylan Investigational Site
[Recruiting]
Budapest, Hungary
Mylan Investigational Site
[Recruiting]
Debrecen, Hungary
Mylan Investigational Site
[Recruiting]
Gyod, Hungary
Mylan Investigational Site
[Recruiting]
Gyula, Hungary
Mylan Investigational Site
[Recruiting]
Miskolc, Hungary
Mylan Investigational Site
[Recruiting]
Nyiregyhaza, Hungary
Mylan Investigational Site
[Recruiting]
Szekszard, Hungary
Mylan Investigational Site
[Recruiting]
Szolnok, Hungary
India
Mylan Investigational Site
[Recruiting]
Ahmedabad, India
Mylan Investigational Site
[Recruiting]
Bangalore, India
Mylan Investigational Site
[Recruiting]
Chennai, India
Mylan Investigational Site
[Recruiting]
Gurgaon, India
Mylan Investigational Site
[Recruiting]
Hyderabad, India
Mylan Investigational Site
[Recruiting]
Jaipur, India
Mylan Investigational Site
[Recruiting]
Karamsad, India
Mylan Investigational Site
[Recruiting]
Madurai, India
Mylan Investigational Site
[Recruiting]
Mumbai, India
Mylan Investigational Site
[Recruiting]
Nashik, India
Mylan Investigational Site
[Recruiting]
Pune, India
Mylan Investigational Site
[Recruiting]
Surat, India
Mylan Investigational Site
[Recruiting]
Vijaywada, India
Latvia
Mylan Investigational Site
[Recruiting]
Daugavpils, Latvia
Mylan Investigational Site
[Recruiting]
Leipaja, Latvia
Mylan Investigational Site
[Recruiting]
Riga, Latvia
Peru
Mylan Investigational Site
[Not yet recruiting]
Arequipa, Peru
Mylan Investigational Site
[Not yet recruiting]
Lima, Peru
Mylan Investigational Site
[Not yet recruiting]
Surquillo, Peru
Romania
Mylan Investigational Site
[Recruiting]
Brasov, Romania
Mylan Investigational Site
[Recruiting]
Bucharest, Romania
Mylan Investigational Site
[Recruiting]
Bucuresti, Romania
Mylan Investigational Site
[Recruiting]
Cluj- Napoca, Romania
Mylan Investigational Site
[Recruiting]
Constanta, Romania
Mylan Investigational Site
[Recruiting]
Craiva, Romania
Mylan Investigational Site
[Recruiting]
Filimon Sirbu, Romania
Mylan Investigational Site
[Recruiting]
Iasi, Romania
Mylan Investigational Site
[Recruiting]
Oradea, Romania
Mylan Investigational Site
[Recruiting]
Timisoara, Romania
Russian Federation
Mylan Investigational Site
[Recruiting]
Arkhangelsk, Russian Federation
Mylan Investigational Site
[Recruiting]
Ivanovo, Russian Federation
Mylan Investigational Site
[Recruiting]
Kazan, Russian Federation
Mylan Investigational Site
[Recruiting]
Kursk, Russian Federation
Mylan Investigational Site
[Recruiting]
Moscow, Russian Federation
Mylan Investigational Site
[Recruiting]
Rostov-On-Don, Russian Federation
Mylan Investigational Site
[Recruiting]
Ryazan, Russian Federation
Mylan Investigational Site
[Recruiting]
Samara, Russian Federation
Mylan Investigational Site
[Recruiting]
St. Petersburg, Russian Federation
Serbia
Mylan Investigational Site
[Recruiting]
Belgrade, Serbia
Mylan Investigational Site
[Recruiting]
Kamenica, Serbia
Mylan Investigational Site
[Recruiting]
Sremska, Serbia
Slovakia
Mylan Investigational Site
[Recruiting]
Bardejov, Slovakia
Mylan Investigational Site
[Recruiting]
Kosice, Slovakia
Mylan Investigational Site
[Recruiting]
Nove Zamky, Slovakia
Mylan Investigational Site
[Recruiting]
Trnava, Slovakia
South Africa
Mylan Investigator Site
[Recruiting]
Bloemfontein, South Africa
Mylan Investigator Site
[Recruiting]
Durban, South Africa
Mylan Investigational Site
[Recruiting]
George, South Africa
Mylan Investigational Site
[Recruiting]
Johannesburg, South Africa
Mylan Investigator Site
[Recruiting]
Kraaifontein, South Africa
Mylan Investigational Site
[Recruiting]
Port Elizabeth, South Africa
Mylan Investigational Site
[Recruiting]
Pretoria, South Africa
Mylan Investigational Site
[Recruiting]
Vereeniging, South Africa
Thailand
Mylan Investigator Site
[Recruiting]
Bangkok, Thailand
Mylan Investigator Site
[Recruiting]
Chiang mai, Thailand
Mylan Investigator Site
[Recruiting]
Phitsanulok, Thailand
Mylan Investigator Site
[Recruiting]
Rajthavee, Thailand
Mylan Investigator Site
[Recruiting]
Songkla, Thailand
Turkey
Mylan Investigator Site
[Recruiting]
Ankara, Turkey
Mylan Investigator Site
[Recruiting]
Istanbul, Turkey
Mylan Investigator Site
[Recruiting]
Izmir, Turkey
Mylan Investigator Site
[Recruiting]
Kocaeli, Turkey
Ukraine
Mylan Investigator Site
[Recruiting]
Cherkassy, Ukraine
Mylan Investigator Site
[Recruiting]
Chernivtsi, Ukraine
Mylan Investigator Site
[Recruiting]
Dnipropetrovsk, Ukraine
Mylan Investigator Site
[Recruiting]
Lutsk, Ukraine
Mylan Investigator Site
[Recruiting]
Lviv, Ukraine
Mylan Investigator Site
[Recruiting]
Sumy, Ukraine
Mylan Investigator Site
[Recruiting]
Uzhgorod, Ukraine
Open or close this module IPDSharing
Plan to Share IPD:
Open or close this module References
Links:
Available IPD/Information:

Scroll up to access the controls Scroll to the Study top

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services